Strategic Communication and Public Relations

Meyenburg Prize 2019 for outstanding research on leukemia

No. 51 | 06/11/2019 | by Koh

The Meyenburg Prize 2019, which carries prize money of 50,000 euros, goes to Benjamin L. Ebert from the Dana-Farber Cancer Institute in Boston for his outstanding research results on the pathogenesis and treatment of leukemia. The award ceremony will take place on Thursday, November 7, 2019 as part of a symposium at the German Cancer Research Center.

Benjamin L. Ebert (left), Stefan Fröhling (Managing Director of NCT Heidelberg)
© Carina Kircher/DKFZ

"Benjamin Ebert is a highly creative and multifaceted scientist. His work has led to important new findings in various areas of cancer research that have made a crucial contribution to improving our understanding of cancer. His research results also have a direct impact on diagnosis and treatment," explained Stefan Fröhling, Director of the Meyenburg Foundation and Managing Director of NCT Heidelberg. "The Meyenburg Prize 2019 recognizes Benjamin Ebert's outstanding contribution to improving clinical care for cancer patients through high-quality research."

One of the results from Ebert's laboratory that has attracted the most attention was the identification of genetic mutations in blood and bone marrow cells that predispose older people to developing leukemia. Individuals with this "pre-malignant syndrome" do not meet the criteria for a diagnosis of leukemia, even though the same mutations occur in leukemia patients, as discovered by Ebert and his colleagues from the genome data of tens of thousands of people. People with this "CHIP syndrome" have a tenfold higher risk of developing leukemia than the general population; they also have a considerably higher overall mortality rate and, to the researchers' surprise, a higher risk of cardiovascular diseases. Patients who have been diagnosed as having CHIP can now be closely monitored for leukemia to allow treatment to be started as early as possible.

Benjamin Ebert also revealed the mode of action of an important cancer drug: Lenalidomide, which is related to thalidomide, is effective against certain types of multiple myeloma. Along with related drugs, the substance leads to degradation of certain cancer-promoting transcription factors in cells, which in turn reduces cancer growth. These findings were the starting point for a completely new area of research in which huge efforts are now being undertaken to develop drugs that are able to degrade cancer-promoting proteins.

Benjamin L. Ebert
© Carina Kircher/DKFZ

Benjamin L. Ebert obtained a bachelor's degree from Williams College, Massachusetts, a doctorate from Oxford University, and an M.D. from Harvard Medical School. He completed a residency at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute. He worked at Brigham and Women's Hospital at Harvard Medical School for ten years before being appointed to the Chair of Medical Oncology at the Dana-Farber Cancer Institute.

Benjamin L. Ebert has received a number of awards and accolades, including most recently his election to the U.S. National Academy of Medicine, the William Dameshek Prize from the American Society of Hematology, and the McCulloch & Till Award from the International Society for Experimental Hematology.

Based at the German Cancer Research Center, the Meyenburg Foundation has been awarding the prize since 1981. Dr Marion Meyenburg, the daughter of the founders Wilhelm and Maria Meyenburg, will be presenting this year's prize in person at the end of the symposium. The prize is awarded annually for outstanding achievements in the field of cancer research and is one of Germany's science awards with the highest prize money. The importance of the award can also be seen from the fact that many of the researchers who have won the Meyenburg Prize are also Nobel laureates: Andrew Fire, winner of the Meyenburg Prize 2002, was awarded the Nobel Prize for Medicine in 2006; Elizabeth Blackburn, winner of the Meyenburg Prize 2006, was awarded the Nobel Prize for Medicine in 2009; Shinya Yamanaka, winner of the Meyenburg Prize 2007, was also awarded the Nobel Prize for Medicine in 2012; Stefan Hell, winner of the Meyenburg Prize 2011, won the Nobel Prize for Chemistry in 2014.

In addition to Benjamin Ebert, the speakers at the Meyenburg Symposium 2019 will be Hartmut Döhner (Ulm University Hospital), Richard Rosenquist Brandell (Karolinska Institute, Stockholm), Rocio Sotillo (DKFZ), and Winette van der Graaf (Netherlands Cancer Institute, Amsterdam). The event will be held at DKFZ's Communication Center from 3.30 pm on Thursday, November 7, 2019. The symposium and award ceremony are open to anyone interested in the event.

*CHIP: clonal hematopoiesis of indeterminate potential

The program is available for downloading:
www.dkfz.de/de/aktuelles/download/Meyenburg-Cancer-Research-Award-Symposium-2019-Program.pdf 

 

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS